-
Annual inventory: analysis of financing events in the field of artificial intelligence pharmaceutical R&D platform in 2022
Time of Update: 2023-02-03
On April 12, 2021, StoneWise, a platform technology company driven by artificial intelligence technology for the research and development of innovative drugs, announced the completion of Series B+ and Series B financing, with a total financing of US$100 million.
-
New drugs The "first" new drugs approved by the FDA in 2022: involving TCR therapy, fecal bacterial therapy, bispecific antibodies, gene therapy, etc
Time of Update: 2023-02-03
Anti-CD20 monoclonal antibody for the treatment of RMSIn February 2022, the FDA approved the PK (pyruvate kinase) activator Pyrukynd (mitapivat) for the treatment of adult patients with PK deficiency and hemolytic anemia.
-
ProQR and Eli Lilly expand RNA editing collaboration, shares jump 63%
Time of Update: 2023-02-03
75 billionOriginal English text: _mstmutation="1" _msthash="220730" _msttexthash="10499125"> On December 22, Eli Lilly and Company partnered with ProQR Therapeutics jointly announced the expansion of its licensing and collaboration agreement to expand collaboration on RNA editing technologies with a focus on the discovery, development and commercialization of new gene drugs.
-
Biotech industry 2023, the darkest and the new rotation
Time of Update: 2023-02-03
The biotechnology industry has turned from bull to bear, and the core inducing factor is the continuous "high-pressure" policy:Centralized procurement + medical insurance negotiation is the "sword of Damocles" hanging over the heads of pharmaceutical companies; The release of the "Guidelines for Clinical R&D of Antitumor Drugs Oriented by Clinical Value" is the beginning of the supply-side reform of innovative drugs.
-
Inventory of the research progress of small molecule tumor immunotherapy drugs, what kind of research and development trends are revealed?
Time of Update: 2023-02-03
Originally developed by Aduro Biotechnology and later licensed to Novartis, ADU-S100 is a cyclic dinucleotide immunomodulator administered by direct intratumoral injection, either as a single agent or in combination with cytotoxic chemotherapy, targeted therapy, or checkpoint inhibitors, and is currently undergoing II clinical trials for metastatic head and neck cancer and squamous cell carcinoma (NCT03937141).
-
Cytomx shares jumped 60 percent with a $1.2 billion partnership with Moderna
Time of Update: 2023-02-03
summarysummaryCytomx's proantibodies have reached cooperation with many large companies, including BMS, Astellas, Moderna, etc.
summarysummaryCytomx's proantibodies have reached cooperation with many large companies, including BMS, Astellas, Moderna, etc.
Cytomx's proantibodies have reached cooperation with many large companies, including BMS, Astellas, Moderna, etc.
-
12 antibody drugs approved for the first time! 20% pipeline growth inventory of antibody drugs approved in 2022
Time of Update: 2023-02-03
Antibody drugs under FDA/EMA approval Source: ReferencesIn addition to new drugs already under approval, 17 antibody drugs in the field of oncology are expected to submit marketing applications to regulatory authorities by the end of this year or next year (Table 4), including 5 bispecific antibodies and 2 ADCs. Table 4.
-
Express $130 million to help develop an innovative drug discovery platform for undruggable targets
Time of Update: 2023-02-03
com/companynews/belharra-therapeutics-debuts-with-130-million-in-funding/ Belharra's integrated chemical proteomics-based drug development engine overcomes the limitations of traditional high-throughput screening by exploring protein/ligand interactions in the cell's natural environment through a unique library of photoaffinity-based chemical probes.
-
The domestic IBD market is expected to exceed 10 billion next year, and drug research and development is still in the early stages
Time of Update: 2023-02-03
Inflammatory bowel disease (IBD) includes Crohn's disease (CD) and ulcerative colitis (UC) is a recurrent and inflammatory disease characterized by intestinal inflammation and epithelial injury that a
-
Professor Yao Chen and Mr. Ge Yongbin had an in-depth conversation on "Compliance and Challenges of Real-World Data Research"!
Time of Update: 2023-02-03
As a medical research, the data is not only limited to the hospital, but also includes additional data collected according to the purpose of the study, especially follow-up data, when it is not enough to have universal informed consent, but also to explain it clearly to the data provider, because they have the individual right to know.
-
2023 Pharmaceutical Annual View: Finding the Next Increment
Time of Update: 2023-02-03
The long road is dangerous, and the medicine melts the circleIn addition to using new technologies such as continuous flow and synthetic biology to reduce costs, APIs/intermediates should be more open and diversified, and the MAH policy and the upstream and downstream of the industrial chain can be used to form a bundled relationship of equity and sharing to develop incremental business.
-
Long-acting HGH Imperative: Milestone! Longpei auxin "beats" the daily preparation head-to-head
Time of Update: 2023-02-03
Longpei auxin is superior to HGH daily formulation, Longpei auxin "beats" HGH daily preparations for the first time head-to-head, and is currently the only product that has demonstrated long-acting efficacy compared to HGH daily preparations through well-designed randomized controlled trialsProfessor Li Yanhong, as an important participant in the phase 3 key clinical trial in China, has a very intuitive feeling about Longpei auxin, she said: "The advent of polyethylene glycol (PEG)ated growth hormone can be said to be a milestone!
-
$660 million! Gilead and EVOQ agree on immunotherapy
Time of Update: 2023-02-03
Original link: _mstmutation="1" _msthash="220729" _msttexthash="6888128"> EVOQ's technology is designed to enable lymphatic-targeted delivery of disease-specific antigens that have been optimized to deliver antigens to restore immune tolerance.
-
Remote decentralized clinical trials on the rise of the EU and UK
Time of Update: 2023-02-03
Decentralized clinical trials (DCTs) differ from traditional clinical trials in that they contain a "remote" element that enables activities such as consent, treatment management, data collection, and monitoring to be conducted remotely, for example, at a patient's home.
-
Gene therapy at home and abroad is looking forward to next year
Time of Update: 2023-02-03
Figure 3 Pipeline progress of gene editing companies (Source: official websites of each company; Organized by Fengshuo Venture Capital)In 2023, the first product of the leading CRISPR company will submit a rolling listing application; VCTX210/211, a synonymous β cell replacement therapy for the treatment of diabetes, by CRISPR and ViaCyte, has entered clinical trials.
-
CanSino announces clinical data on inhaled and intramuscular vaccines
Time of Update: 2023-02-03
(2) ImmunogenicityThe test results of the original true virus neutralizing antibody showed that on the basis that the level of the pre-antibody was close to negative, the GMT of the inhaled antibody reached 672 28 days after the booster vaccination, which was higher than the 583 in the intramuscular group, which was much higher 59 in the inactivated group.
-
More than 350 drugs will increase in price, including Pfizer, GSK, BMS, AZ and Sanofi
Time of Update: 2023-02-03
Recently, according to Reuters, according to healthcare research company 3 Axis Advisors According to the data analyzed, multinational big pharmaceutical companies including Pfizer, GlaxoSmithKline, Bristol-Myers Squibb, AstraZeneca and Sanofi plan to raise 350 in the United States in early January 2023 The price of a variety of unique drugs.
-
Junshi VV116 Announces Phase III Clinical Data for the First Time!
Time of Update: 2023-02-03
On December 29, Junshi Biologics' oral nucleoside anti-novel coronavirus (SARS-CoV-2) drug VV116 (JT001) was head-to-head Pfizer Paxlovid Phase III clinical data on treatment with mild to moderate COV
-
32 clinical trials worth watching in 2023
Time of Update: 2023-02-03
Yesterday, we reviewed the top 10 potential blockbuster therapies that could be approved this year. Today, let's look ahead to the clinical trials worth watching in 2023. Recently, Evaluate released a
-
2022 FDA Approved Drug Analysis (Part I)
Time of Update: 2023-02-03
12 Pluvicto Indications: Prostate cancerIndications: Prostate cancerR&D company: NovartisR&D company: NovartisDate of approval: 3 JanuaryDate of approval: 3 JanuaryPluvicto is approved for the treatment of adults with advanced prostate-specific membrane antigen-positive, metastatic castration-resistant prostate cancer (mCRPC) who have received androgen receptor pathway inhibitor therapy and taxane-based chemotherapy.
